

For Further Information Contact:

Roy Wolvin
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com

For Immediate Release:

Nymox Pursuing New Approaches to an Old Disease

HASBROUCK HEIGHTS, NJ (November 20, 2006) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is taking innovative and unique approaches to the diagnosis and treatment of Alzheimer's disease. It is widely recognized that new methods of treating and diagnosing Alzheimer's disease are urgently needed in the face of an impending world-wide epidemic of Alzheimer's disease. Currently, an estimated 4.5 million Americans and more than 15 million people around the world suffer from the disease. By 2050, this number is expected to triple, creating enormous burdens on health-care systems, care-givers and communities.

Nymox's AD drug development programs focus on novel proprietary approaches to the diagnosis and treatment of Alzheimer's disease. One such program targets spherons, tiny balls of densely packed protein found in the human brain and believed by Nymox scientists to be a major cause of senile plaques. Senile plaques are found abundantly in the brains of patients with Alzheimer's disease and are believed by many researchers to play a pivotal role in the fatal illness. Nymox has used spheron-based drug screening methods to discover, develop and test unique drug candidates aimed at limiting the formation of Alzheimer plaques from spherons and thus slowing or stopping the progression of the disease.

Another Nymox AD program targets neural thread protein (NTP), the brain protein measured by AlzheimerAlert™, the Company's urine based diagnostic aid for AD. AlzheimerAlert™ is currently available in Europe as a kit with the CE Mark and in the US as a CLIA certified clinical reference laboratory test service. Nymox has developed new drug candidates designed to inhibit the effects of over-production of NTP in the AD brain.

Nymox's product development programs are supported by an extensive worldwide patent portfolio encompassing a wide range of products, drug candidates and targets. Currently Nymox and its subsidiaries own or have licensed exclusive rights to several hundred patents and patent applications in the U.S. and other countries around the world.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.